Company intelligence / Profile preview

IM Cannabis

Kibbutz Glil-Yam / Tel Aviv, Tel Aviv District, Israelimcannabis.com ↗

Ownership: Public · IMCC
Employees: ~95
Development stage: Commercial

Overview

IM Cannabis is a commercial-stage international medical cannabis company providing premium products to patients in Israel and Germany. The company has exited the Canadian market to focus on its core markets, leveraging proprietary data, advanced cultivation, and distribution networks. It operates through subsidiaries such as Focus Medical Herbs Ltd. in Israel and Adjupharm GmbH in Germany. Its products are available via pharmacies, retail outlets, online platforms, and direct distribution channels.

Therapeutic areas: GastroenterologyPsychiatryNeurology
Modalities: Plant-derived therapy (medical cannabis)Small molecule (cannabinoids)
Industry: Biotech

Financials

Market cap: $358.4K
Total revenue: $38.9M
Enterprise value: $9M

Beyond the preview

Go deeper on IM Cannabis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM Cannabis.